Post COVID symptom burden in patients supported with extracorporeal membrane oxygenation: A prospective 2-year follow-up analysis.

IF 1.4 4区医学 Q4 ENGINEERING, BIOMEDICAL

International Journal of Artificial Organs Pub Date : 2025-03-01 Epub Date: 2025-03-12 DOI:10.1177/03913988251322710

Rayan Cheaban, Anna L Rogge, Katharina E Schaeper, Nicole Weinrautner, Thomas Kirschning, Frank Bruenger, Maria R Serrano, Markus Rudloff, Iris Barndt, Marcus Wiemer, René Schramm, Jan F Gummert, Sabina Pw Guenther

{"title":"Post COVID symptom burden in patients supported with extracorporeal membrane oxygenation: A prospective 2-year follow-up analysis.","authors":"Rayan Cheaban, Anna L Rogge, Katharina E Schaeper, Nicole Weinrautner, Thomas Kirschning, Frank Bruenger, Maria R Serrano, Markus Rudloff, Iris Barndt, Marcus Wiemer, René Schramm, Jan F Gummert, Sabina Pw Guenther","doi":"10.1177/03913988251322710","DOIUrl":null,"url":null,"abstract":"Objectives: A systematic characterization of the long-term sequelae after the severest form of COVID-19 requiring ECMO-therapy is lacking. Here, we present 2-year follow-up data of COVID-19 ECMO survivors, and analyze the cardiopulmonary, neurocognitive, psychological, and functional status, plus health-related quality of life (HRQL).Methods: From 04/2020 to 09/2021, 60 COVID patients were supported with ECMO. Survival to discharge was 40.0% (n = 24), and 6-month survival was 33.3% (n = 20). Follow-ups were performed via phone and mail using validated tools. Six-month outcomes have been published before.Results: At 2 years, 20 patients were alive. N = 19 agreed to participate in this study (median age 57.0 (45.0-63.0) years, 21.1% female). The cardiopulmonary status was satisfactory (78.9% in NYHA level I-II). Altogether, 84.2% were vastly independent in daily life. However, 47.4% still showed cognitive impairment, 21.1% moderate, 15.8% severe depression, and 15.8% posttraumatic stress disorder symptoms. HRQL subscale results were similar to 6 months, but patients self-rated their overall health significantly better (70.0% (50.0%-80.0%) vs 50.0% (30.0%-80.0%), p = 0.04). The number of patients working was increasing. Social life remained markedly affected.Conclusions: Two-year outcomes in COVID-19 ECMO patients were stable to improving as compared to 6-month results. However, long-term impairments affected all aspects of life. Long COVID specifically, and post ECMO sequelae in general need to be characterized further to enable maximum recovery.","PeriodicalId":13932,"journal":{"name":"International Journal of Artificial Organs","volume":" ","pages":"146-154"},"PeriodicalIF":1.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Artificial Organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/03913988251322710","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: A systematic characterization of the long-term sequelae after the severest form of COVID-19 requiring ECMO-therapy is lacking. Here, we present 2-year follow-up data of COVID-19 ECMO survivors, and analyze the cardiopulmonary, neurocognitive, psychological, and functional status, plus health-related quality of life (HRQL).

Methods: From 04/2020 to 09/2021, 60 COVID patients were supported with ECMO. Survival to discharge was 40.0% (n = 24), and 6-month survival was 33.3% (n = 20). Follow-ups were performed via phone and mail using validated tools. Six-month outcomes have been published before.

Results: At 2 years, 20 patients were alive. N = 19 agreed to participate in this study (median age 57.0 (45.0-63.0) years, 21.1% female). The cardiopulmonary status was satisfactory (78.9% in NYHA level I-II). Altogether, 84.2% were vastly independent in daily life. However, 47.4% still showed cognitive impairment, 21.1% moderate, 15.8% severe depression, and 15.8% posttraumatic stress disorder symptoms. HRQL subscale results were similar to 6 months, but patients self-rated their overall health significantly better (70.0% (50.0%-80.0%) vs 50.0% (30.0%-80.0%), p = 0.04). The number of patients working was increasing. Social life remained markedly affected.

Conclusions: Two-year outcomes in COVID-19 ECMO patients were stable to improving as compared to 6-month results. However, long-term impairments affected all aspects of life. Long COVID specifically, and post ECMO sequelae in general need to be characterized further to enable maximum recovery.

查看原文本刊更多论文

体外膜氧合支持患者的COVID后症状负担：一项前瞻性2年随访分析

目的：缺乏对需要ecmo治疗的最严重形式的COVID-19后长期后遗症的系统描述。在这里，我们提供了COVID-19 ECMO幸存者的2年随访数据，并分析了心肺、神经认知、心理和功能状态，以及健康相关生活质量（HRQL）。方法：2020年4月至2021年9月，对60例COVID - 19患者进行ECMO支持。出院生存率为40.0% (n = 24)， 6个月生存率为33.3% （n = 20）。随访通过电话和邮件进行，使用有效的工具。6个月的结果之前已经公布过。结果：2年时，20例患者存活。N = 19人同意参加本研究（中位年龄57.0（45.0-63.0）岁，21.1%为女性）。患者心肺状况良好（NYHA I-II级为78.9%）。总的来说，84.2%的人在日常生活中非常独立。然而，仍有47.4%的人表现出认知障碍，21.1%的人表现出中度抑郁，15.8%的人表现出重度抑郁，15.8%的人表现出创伤后应激障碍症状。HRQL亚量表结果与6个月相似，但患者自评整体健康状况明显改善(70.0% （50.0%-80.0%)vs 50.0% (30.0%-80.0%), p = 0.04）。参加工作的病人越来越多。社会生活仍然受到明显影响。结论：与6个月的结果相比，COVID-19 ECMO患者的两年结果稳定至改善。然而，长期损伤会影响生活的方方面面。特别是长冠状病毒，以及一般的ECMO后后遗症需要进一步表征，以实现最大程度的恢复。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Artificial Organs 医学-工程：生物医学

CiteScore

3.40

自引率

5.90%

发文量

审稿时长

3 months

期刊介绍： The International Journal of Artificial Organs (IJAO) publishes peer-reviewed research and clinical, experimental and theoretical, contributions to the field of artificial, bioartificial and tissue-engineered organs. The mission of the IJAO is to foster the development and optimization of artificial, bioartificial and tissue-engineered organs, for implantation or use in procedures, to treat functional deficits of all human tissues and organs.